Women with myeloproliferative neoplasms appear to have successful pregnancies with better outcomes than would be anticipated from previously published reports, according to a study published in the British Journal of Haematology.1

Evidence suggests that women with myeloproliferative neoplasms such as polycythemia vera and essential thrombocythemia have a higher risk of maternal and fetal complications, which ultimately poses challenges during pregnancy.

To examine maternal and fetal outcomes of women with myeloproliferative neoplasms, researchers analyzed data from 58 pregnant women with essential thrombocythemia, polycythemia, or myelofibrosis who participated in the United Kingdom Obstetric Surveillance System between 2010 and 2012.

During that period, there were 58 live births. Results showed that the incidence of miscarriage was 1.7% (95% CI, 0.04-9.24) and the perinatal mortality rate was 1.7% (95% CI, 0.44-92.36), including both live and stillbirths.

Researchers also found that the incidence of pre-eclampsia, postpartum hemorrhage, and postpartum hematoma were 9%, 9%, and 3.5%, respectively. No maternal deaths or thrombotic events were reported.

A total of 45% of mothers required induced delivery, with all undergoing Caesarean section. Most women delivered at term, with 22% of neonates being below the tenth percentile for growth and 13% requiring admission to the neonatology unit.

Of note, there were no neonatal deaths.

Reference

1. Alimam S, Bewley S, Chappell LC, et al. Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br J Haematol. 2016 Sep 9. doi: 10.1111/bjh.14289. [Epub ahead of print]